Chicken anaemia virus (CAV) is a common viral agent in chickens worldwide. CAV belongs to the genus Gyrovirus of the Anelloviridae, which have characteristics of circular single-stranded DNA viruses . This virus frequently results in immunosuppression and anaemia in young chickens due to the destruction of T lymphoid tissue and aplasia of bone marrow, respectively, during virus infection [2–5]. Over 55% of the mortality rate and 80% of the morbidity rate were reported once the chicks were infected with CAV . Therefore, determining how to prevent CAV infection in the poultry industry has becomes an important challenge. The CAV virion lacks an envelope around its capsid coat, and it shows significantly high resistance to environmental stress or chemical agents. Currently, an attenuated live vaccine is available and effective for immunization of chickens for controlling CAV infection. However, young chicks less than 2 weeks-old are susceptible to CAV infection when the live vaccine was used . This consequence has led to the development of a subunit vaccine, including DNA or protein based vaccine, over the past decade.